Is the price fair?
What HSIC's price assumes
Henry Schein trades at 26.9× earnings against 29.9× for the median Healthcare name, cheaper than its own group.
26.9
Trailing P/E · Healthcare median 29.9 · cheaper than the typical name in its group
- Price / sales
- 0.63
Price / sales · as of 2026-Q1
- Free cash flow yield
- 4.9%
Free cash flow yield · Healthcare median 4.5%
- Growth the price implies
- +5.9%
Growth the price implies · The price pays for +5.9% free cash flow growth a year for a decade; the business has delivered +1.3% a year over the last three.
Details›
- Price / book2026-Q1
- 2.56
- Healthcare median P/E362 names
- 29.9
- Free cash flow, trailing twelve months
- $445M
- Market capitalisation
- $9.10B
- 3-year revenue growth
- +2.2%
- 3-year free cash flow growth
- +1.3%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $61.58 |
| Its own P/E history, median | $68.27 |
| Its own P/E history, upper quartile | $78.63 |
| 52-week range | $62.03 – $90.86 |
| Today | $88.86 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.